This new test will be available through Clarient’s PATHSiTE virtual reporting tool and accessible to the company’s entire pathology network.
Clarient said that the new test is based on a unique and patent-protected combination of four genes that have been shown to accurately identify the presence of Grade 3 or higher prostate cancer cells in prostate tissue. The association of these four genes with prostate cancer was discovered by Health Discovery using its patented SVM and SVM-RFE pattern recognition technology.
The two companies also announced that in order to insure market uptake of the new prostate cancer test, they will transition to a non-exclusive agreement to allow for licensing to additional laboratories. Under the amended agreement, Clarient will retain the exclusive rights for a prognostic test which may be developed in the future in conjunction with Health Discovery.